Keywords: US, Boehringer Ingelheim, Mirapex, pramipexole, Pharmacy directors

US uptake of Boehringer Ingelheim’s Mirapex ER for Parkinson's disease will be inhibited by generic pramipexole

Article | 01 April 2010

Print This

In the USA, the uptake of German drug major Boehringer Ingelheim's pramipexole ER, the once-daily formulation of its market leading ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in